Asked by: Chris Evans (Labour (Co-op) - Caerphilly)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of limited fresh-freezing capacity on patients’ access to emerging cancer (a) testing and (b) treatments.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Fresh-freezing, also referred to as snap-freezing, is a standard technique used by pathology networks to preserve tissue architecture without chemical fixatives, allowing for subsequent molecular or histological analysis, typically supporting research or advanced diagnostic applications.
Pathology services in England are delivered through 27 regional pathology networks, and offer a comprehensive range of tests, including the analysis of brain tissues.
Individual pathology services maintain their own standard operating procedures (SOPs) for fresh tissue samples and for the snap-freezing of tissue samples. These SOPs outline local capabilities and practices.
It is important that everyone, regardless of where they live, can access the latest innovations in the health and care system through research. The Department invests over £1.6 billion each year in research through the National Institute of Health and Care Research (NIHR). The NIHR’s investments for capital equipment, technology, and modular buildings support NHS trusts across England to deliver high-quality research to improve the health of the population. This investment includes cutting edge research equipment and fixed assets such as ultra-low and cryogenic freezers, to strengthen research capacity and improve access to samples for research.
The Department is exploring options to expand brain tissue freezing capacity.
Asked by: Chris Evans (Labour (Co-op) - Caerphilly)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of (a) fresh-freezing, (b) snap-freezing and (c) flash frozen capacity for brain cancer tissue samples across NHS trusts in England.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Fresh-freezing, also referred to as snap-freezing, is a standard technique used by pathology networks to preserve tissue architecture without chemical fixatives, allowing for subsequent molecular or histological analysis, typically supporting research or advanced diagnostic applications.
Pathology services in England are delivered through 27 regional pathology networks, and offer a comprehensive range of tests, including the analysis of brain tissues.
Individual pathology services maintain their own standard operating procedures (SOPs) for fresh tissue samples and for the snap-freezing of tissue samples. These SOPs outline local capabilities and practices.
It is important that everyone, regardless of where they live, can access the latest innovations in the health and care system through research. The Department invests over £1.6 billion each year in research through the National Institute of Health and Care Research (NIHR). The NIHR’s investments for capital equipment, technology, and modular buildings support NHS trusts across England to deliver high-quality research to improve the health of the population. This investment includes cutting edge research equipment and fixed assets such as ultra-low and cryogenic freezers, to strengthen research capacity and improve access to samples for research.
The Department is exploring options to expand brain tissue freezing capacity.
Asked by: Chris Evans (Labour (Co-op) - Caerphilly)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will make an assessment of the adequacy of the NHS’s capacity for fresh freezing of (a) tumour and (b) other tissue samples.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Fresh-freezing, also referred to as snap-freezing, is a standard technique used by pathology networks to preserve tissue architecture without chemical fixatives, allowing for subsequent molecular or histological analysis, typically supporting research or advanced diagnostic applications.
Pathology services in England are delivered through 27 regional pathology networks, and offer a comprehensive range of tests, including the analysis of brain tissues.
Individual pathology services maintain their own standard operating procedures (SOPs) for fresh tissue samples and for the snap-freezing of tissue samples. These SOPs outline local capabilities and practices.
It is important that everyone, regardless of where they live, can access the latest innovations in the health and care system through research. The Department invests over £1.6 billion each year in research through the National Institute of Health and Care Research (NIHR). The NIHR’s investments for capital equipment, technology, and modular buildings support NHS trusts across England to deliver high-quality research to improve the health of the population. This investment includes cutting edge research equipment and fixed assets such as ultra-low and cryogenic freezers, to strengthen research capacity and improve access to samples for research.
The Department is exploring options to expand brain tissue freezing capacity.
Asked by: Kim Johnson (Labour - Liverpool Riverside)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what estimate he has made of the funding required to ensure equitable access to tissue-freezing services for cancer patients across England; and whether his Department is taking steps to reduce regional disparities.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Pathology services in England are delivered through 27 regional pathology networks, and offer a comprehensive range of tests, including the analysis of brain tissues. Individual pathology services maintain their own standard operating procedures (SOPs) for fresh, or snap-freezing, of tissue samples. These SOPs outline local capabilities and practices.
It is important that everyone, regardless of where they live, can access the latest innovations in the health and care system through research. The Department invests over £1.6 billion each year in research through the National Institute of Health and Care Research (NIHR). The NIHR’s investments for capital equipment, technology, and modular buildings support National Health Service trusts across England to deliver high-quality research to improve the health of the population. This investment includes cutting edge research equipment and fixed assets such as ultra-low and cryogenic freezers, to strengthen research capacity and improve access to samples for research.
The Department is exploring options to expand brain tissue freezing capacity.
Asked by: Luke Evans (Conservative - Hinckley and Bosworth)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what estimate he has made of the (a) number of pharmacy contractors who are due outstanding payments from the NHSBSA for Pharmacy First Services and (b) total value of outstanding payments.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.
Asked by: Luke Evans (Conservative - Hinckley and Bosworth)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that the NHSBSA provide timely payments to pharmacists carrying out Pharmacy First consultations.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.
Asked by: Alex Brewer (Liberal Democrat - North East Hampshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential impact of retail sold magnets on the safety of cerebrospinal fluid shunts programmable externally by magnets.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for ensuring that medicines, medical devices, and blood components for transfusions on the market in the United Kingdom are safe, effective, and manufactured to the highest standards of quality. The Medical Devices Regulations 2002 (MDR 2002) establish the statutory framework that medical devices must meet in order to comply with these standards.
All medical devices, including cerebrospinal fluid shunts programmable externally by magnets, must comply with the MDR 2002, which include bearing the UKCA or CE marking on the packaging or labelling of the device. Manufacturers or their UK representatives must monitor use of these devices when used in the UK. The manufacturer holds the legal responsibility for obtaining the necessary certification and registering their medical devices with the MHRA, the UK Competent Authority. Higher risk medical devices are assessed and approved by Approved Bodies in the UK or Notified Bodies in the European Union.
As part of meeting the requirements of the regulations, manufacturers have to provide instructions which would include any special operating instructions, any warnings and/or precautions to take, and precautions to be taken as regards exposure, in reasonably foreseeable environmental conditions, to magnetic fields. In addition, some manufacturers provide further standalone information on this topic, an example of which is available at the following link:
Asked by: Charlie Dewhirst (Conservative - Bridlington and The Wolds)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, Pursuant to the answer of 5 January 2026, to Question 96853, on NHS England: Costs what estimate he has made of the (a) gross and (b) net number of civil servants who will leave the Civil Service due to redundancy.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Government’s ambition remains to reduce staff numbers by up to 50% across the Department, NHS England, and the integrated care boards, which is the equivalent to up to 18,000 posts, including a number of Civil Servants, through paid exits via voluntary exits and redundancies, natural attrition, and recruitment controls, combined together. These reductions will be made by March 2028. The overall cost of paid exits across organisations is estimated at approximately £1 billion to £1.3 billion. The calculations remain subject to ongoing policy development and refinement, and are also subject to actual take-up of exit schemes and calculated individual costs. Relevant, material financial information relating to this active policy development will be published in due course in line with transparency obligations. The Government remains committed to reducing unnecessary bureaucracy and duplication, to save more than £1 billion a year by the end of Parliament, which will go directly to improving patient outcomes.
Asked by: Ben Spencer (Conservative - Runnymede and Weybridge)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of support available for families of individuals with substance misuse and addiction.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
From this year, all drug and alcohol treatment and recovery funding will be channelled through the Public Health Grant, with over £13.45 billion allocated across three years, including £3.4 billion ringfenced for drug and alcohol treatment and recovery. Local authorities are responsible for commissioning drug and alcohol treatment and recovery services according to local need and can use this funding to support the families of individuals with a drug and/or alcohol treatment need.
The Department has published guidance specifically for adult treatment, and children and family services on how to effectively work together to support families affected by addiction. This is available at the following link:
Asked by: Rebecca Paul (Conservative - Reigate)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many detransitioners from the Early Intervention Study run by the Tavistock Gender Identity Development Service (GIDS) in 2011-14 have presented to the NHS for either medical injury or regret; and how many detransitioners, in total, have presented to the NHS for either medical injury or regret since the Cass review was commissioned.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
Data and research on detransition has been limited and the number of individuals who may wish to seek help from the National Health Service is not held.
In line with recommendation 25 of the Cass Review, NHS England is developing a clinical pathway for individuals who wish to detransition. Between October and December 2025, NHS England held a 'call for evidence' aimed at healthcare professionals and medical bodies, and the responses will help to shape the development of a care pathway and service specification which NHS England plans to consult on in the summer of 2026.